Publicaciones en las que colabora con Josep Tabernero Caturla (19)

2024

  1. Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence

    Future Oncology, Vol. 20, Núm. 20, pp. 1401-1413

2022

  1. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)

    European Journal of Cancer, Vol. 177, pp. 154-163

2020

  1. The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls

    Expert Opinion on Biological Therapy, Vol. 20, Núm. 1, pp. 15-22

2016

  1. Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH

    Medicina Clinica, Vol. 146, Núm. 11, pp. 511.e1-511.e22

  2. Molecular characterization of HER2-positive (HER2+) metastatic gastric and gastro-esophageal junction cancer patients (mGC): Identification of resistance mechanisms to trastuzumab-based therapy (TTZ)

    Annals of Oncology, Vol. 27, pp. vi213

  3. Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer

    British Journal of Cancer, Vol. 114, Núm. 4, pp. 372-380

2015

  1. Nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: Long-term survival from a phase III trial

    Journal of the National Cancer Institute, Vol. 107, Núm. 2

2013

  1. A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer

    Annals of Oncology, Vol. 24, Núm. 7, pp. 1777-1785

2012

  1. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: A spanish cooperative group for the treatment of digestive tumors study

    Oncologist, Vol. 17, Núm. 7, pp. 947-955

  2. First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Onkologie, Vol. 6, Núm. 2, pp. 96-103

  3. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Oncologist, Vol. 17, Núm. 1, pp. 15-25

  4. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

    PLoS ONE, Vol. 7, Núm. 10

2010

  1. SEOM clinical guidelines for the adjuvant treatment of colorectal cancer

    Clinical and Translational Oncology, Vol. 12, Núm. 11, pp. 724-728

2009

  1. Consensus on the treatment of pancreatic cancer in Spain

    Clinical and Translational Oncology, Vol. 11, Núm. 5, pp. 290-301

  2. Diagnóstico y tratamiento del carcinoma hepatocelular

    Medicina Clinica, Vol. 132, Núm. 7, pp. 272-287

  3. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: Comparative outcomes from the 03-TTD-01 phase III study

    Critical Reviews in Oncology/Hematology, Vol. 70, Núm. 2, pp. 134-144

2007

  1. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: Final report of the Spanish Cooperative Group for the treatment of digestive tumors trial

    Journal of Clinical Oncology, Vol. 25, Núm. 27, pp. 4224-4230

2002

  1. Capecitabine (Xeloda ®) in combination with oxaliplatin: A phase I, dose-escalation study in patients with advanced or metastatic solid tumors

    Annals of Oncology, Vol. 13, Núm. 4, pp. 558-565

1998

  1. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study

    Annals of Oncology, Vol. 9, Núm. 7, pp. 727-731